Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have measured the plasma level of a fucosyltransferase in patients with acute myelogenous leukemia and non-Hodgkin's lymphoma at various stages of the disease and in normal controls. This enzyme transfers the sugar fucose from a guanosine diphosphate-L-fucose donor to high-molecular-weight acceptors with a terminal N-acetyl-glucosamine residue. The enzyme levels of fucosyltransferase in individuals free from disease and in patients with untreated leukemia or lymphoma were comparable. A substantial increase in plasma enzyme level was measured during drug-induced remissions, three weeks after drug therapy. The enzyme level fell to the normal range during unmaintained remissions inpatients with lymphomas; comparable information for the leukemia is not available since all remissions were drug maintained. These data, together with microscopic examination of marrow samples, indicate that the level of this fucosyltransferase is correlated with regeneration of a normal marrow population after chemotherapy. The enzyme assay may prove useful in defining normal bone marrow recovery and in timing cyclic combination chemotherapy in patients with neoplastic disease.
 ...
PMID:Guanosine diphosphate-L-fucose plasma: N-acetylglucosaminide fucosyltransferase as in index of bone marrow hyperplasia after chemotherapy. 27 Oct 43

The diagnosis of non-Hodgkin's lymphoma with spontaneous acute granulocytic leukemia was confirmed by examination of the patient's bone marrow and peripheral blood specimens at the light and electron microscopic level, and by autopsy findings. Only one previous case of simultaneous non-Hodgkin's lymphoma and acute myelomonocytic leukemia with no prior history of chemotherapy, radiotherapy, or both, has been reported. Although the present patient was given no mutagenic therapy, his chronic exposure to an unknown insecticide may have played a leukemogenic role.
 ...
PMID:Simultaneous occurrence of non-Hodgkin's lymphoma and spontaneous acute granulocytic leukemia. 28 Jan 23

A 37 year old man with a non-Hodgkin's lymphoma and a history of heavy alcohol use presented with bilateral palmar pits. Similar lesions were noted in several family members, some of whom had limited use of the hands. Although the patient was referred for evaluation of the palmar pits of the basal cell nevus syndrome, close evaluation revealed the diagnosis of Dupuytren's disease.
 ...
PMID:Dupuytren's disease presenting as palmar pits. 28 78

The development of a second neoplasm is a rare complication in patients with various types of primary malignancy. This report describes two patients with non-Hodgkin's lymphoma who developed adenocarcinoma of the lung and malignant pleural effusion following many years of cytotoxic therapy. The value of cytological examination of the sputum and pleural aspirate, as well as fibreoptic bronchial biopsy in the diagnosis are emphasised. The higher incidence of this complication in patients with lymphocytic type of non-Hodgkin's lymphoma may be due to their longer survival and probable basic immune defects which become overt after chemotherapy.
 ...
PMID:Adenocarcinoma of the lung in non-Hodgkin's lymphoma. 29 12

The lymph node cell populations from 24 patients with non-Hodgkin's lymphoma were investigated for some of the surface characteristics which are used as T- and B-lymphocyte markers. Nineteen of the patients had had no treatment of any kind while the other 5 had had either recent radiotherapy or chemotherapy. Seven lymph nodes from patients without malignant disease and 7 others with reactive changes were also studied. It was found that lymphocytic lymphomas, nodular or diffuse, well or poorly differentiated, had a high proportion of cells which were positive for B-cell markers. Other non-lymphocytic lymphomas had a higher proportion of cells positive for T-cell markers, and were similar to the cells from non-malignant lymph nodes.
 ...
PMID:Description of the cells from the lymph nodes of patients with non-Hodgkin's lymphoma according to some B- and T-cell characteristics. 30 26

It is well known that there are many independent and inter-related clinical and pathologic factors which influence the prognosis of patients with benign and malignant conditions. Lymphocyte level is an index of cell-mediated immunity which is important in host defense against cancer. But it is surprising that a simple test such as peripheral lymphocyte count could be correlated with clinical stages and survival results in patients with Hodgkin's disease, non-Hodgkin's lymphoma and non-lymphomatous solid tumors. Regarding the latter, lymphocyte count had prognostic values in patients with cancer of the bone, Ewing's sarcoma; breast; colon; kidney, neuroblastoma; uterine cervix, and other sites. In general, higher lymphocyte counts before therapy correlated with longer survival. Using newer immunologic techniques, T and B lymphocytes can be identified and the different subtypes of leukemia, immunodeficiency and lymphoproliferative diseases have been studied intensively. Chronic lymphocytic leukemia represents a proliferation of B cells, while the Sezary syndrome represents that of T lymphocytes. There is a qualitative and quantitative disturbance of Blymphocytes in patients with multiple myeloma. In Hodgkin's disease, there is hyperactivity of the B cells and functional defect of the T cells. Finally, the nodular non-Hodgkin's lymphoma resulted from neoplastic transformation of the B lymphocytes. In several nonmalignant autoimmune conditions, abnormality of T-cell or B-cell counts has been reported. For example, T cells were reported to be decreased in patients with ulcerative or granulomatous colitis and in patients with rheumatoid arthritis, However, it needs to be pointed out that, in 1973, Farid and associates (44) reported a significant increase in T and a proportionate reduction of B rosette in 17 patients with untreated Grave's disease and 16 with Hashimoto's thyroiditis as compared with 24 normal and eight goiter controls. In 1975, six publications later, they (143) had to announce a retraction because further studies by them and by other investigators could not repeat the earlier results. Despite variations and lack of standardization of the test systems, some consistent deviations of T-lymphocyte and B-lymphocyte counts have been reported. T lymphocytes were quantitatively decreased in patients with carcinoma of the brain, breast, head and neck, liver, lung and urologic organs and with malignant melanoma. In general, there is a marked decrease of T cells with increasing stage of disease and a return of T cells to normal level after successful therapy. Cellular immunity is depressed, often lasting for years after localized radiation therapy, whether or not the thymus is included in the treatment field...
 ...
PMID:Peripheral lymphocyte count and suppopulations of T and B lymphocytes in benign and malignant diseases. 30 Jan 79

We report the presence of a rosette inhibiting factor (RIF) in the plasma of patients with active Hodgkin's disease. This factor suppresses the rosette forming ability of autologous Active T, Total T, and B lymphocytes with sheep red blood cells, and tends to disappear when clinical remission is achieved. To a lesser extent, the RIF also lowers the Active T, Total T and B-RFC percentages of lymphocytes obtained from normal donors. Although carcinoma and non-Hodgkin's lymphoma patients, as a group, did not exhibit rosette inhibitive properties, certain individuals with these diagnoses did show isolated RIF activity. The RIF could be adsorbed out of plasma using peripheral blood lymphocytes (PBL) from normal controls and appears to be a large heat stable molecule which does not affect PBL viability.
 ...
PMID:T and B-RFC inhibiting factor in plasma from patients with active Hodgkin's disease. 31 39

Pretreatment lymph nodes, bone marrow, and blood were examined in 176 cases of non-Hodgkin's lymphoma. By the criteria of the Lukes and Collins functional--morphological classification, 158 (90%) were B-cell lymphomas and 17 (10%) were T-cell lymphomas. Bone marrow involvement was present in 53% of cases: 51% of B-cell types and 65% of T-cell types. Marrow involvement was most frequent in small lymphocyte (B) (89%), convoluted lymphocyte (60%), and small cleaved follicular center cell (FCC) lymphomas (55%). The pattern of bone marrow involvement was most frequently focal paratrabecular in B-cell lymphomas and diffuse in T-cell lymphomas. Blood involvement was present in 50% of cases with bone marrow lymphoma and generally reflected extensive bone marrow disease. There was a higher incidence of both bone marrow and blood involvement in pediatric patients than in adults.
 ...
PMID:Incidence and patterns of bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. 31 3

The recent developments and results of treatment in Hodgkin's disease suggest that staging laparotomy is indicated in certain selected groups of patients and should not be performed routinely in patients whose therapy is unlikely to be changed by the findings.Early stage nodal Hodgkin's disease is best treated by extended radiotherapy. The exact role of adjuvant chemotherapy is not settled, but there are certain groups of high-risk patients who should receive chemotherapy, such as those with extensive mediastinal disease or advanced IIIA patients. In the advanced stages, chemotherapy assumes the primary role and with the MOPP programme (chlormethine, vincristine, procarbazine, and prednisone), alone or alternating with ABVD (doxorubicin, bleomycin, vinblastine, and imidazole carboxamide), a substantial number of patients can be controlled or cured.The therapeutic approach to non-Hodgkin's lymphoma should be guided mainly by the histological findings, favourable or unfavourable, and to a lesser degree also by the stage of the disease. In these patients, chemotherapy rather than radiotherapy is the treatment of choice. In the favourable histology group, a conservative approach is usually justified in the majority of patients, while in the unfavourable histology group, aggressive combination chemotherapy containing adriamycin is the recommended therapy.In underprivileged populations, the abdominal and intestinal localization of lymphomas is more common than in Europe and North America. Two lymphomas of special interest are Burkitt's lymphoma and intestinal lymphoma in their varying aspects. In both diseases, the importance of environmental factors is highly suggestive. Referral of such patients to centres involved in the management of these diseases is essential.
 ...
PMID:Role of radiotherapy and chemotherapy in the treatment of lymphomas. 31 17

Immunohistochemical and histoogical studies have been performed on paraffin sections of 19 cases of non-Hodgkin's lymphoma (NHL). All the cases were lymphocytic in type and, on the basis of the National Lymphoma Investigation classification, 11 were follicular (six small, three mixed small and large, and two large cell types) and eight were diffuse (four intermediate, three poorly and one well-differentiated types). Marshall's metalophil method revealed a population of dendritic histiocytes in and around the follicles of follicular lymphomas. The distribution of the dendritic cells within the neoplastic follicles resembled the distribution of similar cells in reactive follicles, lending support to the concept of an origin for lymphoma follicles from their reactive counterparts. In the diffuse lesions the dendritic cells were large and more pleomorphic than in the follicular lesions, but these features were not so pronounced as those previously observed in Hodgkin's disease. The PAP sequence was used to demonstrate Ig, and as judged by the types of light and heavy chains in the lymphoma cells, the cases were divided into three groups: Group 1 (eight cases) in which the lymphoma cells contained monotypic Ig; Group 2 (six cases) in which monotypic Ig was probably present; and Group 3 (four cases) where no evidence of monotypic Ig secretion was found. Monotypic Ig was most commonly found in follicular lymphomas, mu kappa secretion being the most frequently identified combination of heavy and light chains. The majority of cases (73 per cent.) were thus clearly derived from B lymphocytes. However, the fact that monoclonality was evident in only a proportion of cases suggested that lymphomas may be polyclonal initially and proportion of cases suggested that lymphomas may be polyclonal initially and that monoclonality is a later development. In addition to the lymphoma cells, normal mature plasma cells containing a high concentration of intracellular Ig were present in all but one of the lesions. The Ig was polytypic, cells containing kappa and lambda chains being present in roughly equal numbers and gamma chains pre-dominating. Extracellular Ig (gamma, mu, kappa, lambda) was also present in many lesions. Collections of small non-lymphomatous lymphocytes were also present in all cases. In eight lesions these appeared to have polytypic surface Ig (mu, kappa, lambda). Dendritic cells mingled with these lymphocytes. Collections of small lymphocytes non-reactive for Ig were also present. These had no association with dendritic histiocytes and might have been T cells. It is concluded that in most cases immunohistochemistry alone provides an insufficient basis for the diagnosis of lymphoma and that disturbance of cellular morphology and tissue architecture remain the most useful criteria on which the diagnosis of lymphoma rests.
 ...
PMID:Non-Hodgkin's lymphomas: an immunohistochemical and histological study. 31 5


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>